Rafael Pharmaceuticals Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Newark NJ United States (2000)

Organization Overview

First Clinical Trial
2008
NCT00741403
First Marketed Drug
2004
acetaminophen (tylenol)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

CORNERSTONE | Cornerstone Pharmaceuticals | Cornerstone Pharmaceuticals, Inc. | Rafael Pharmaceuticals Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Carcinoma (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 2)

Preleukemia (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Clear Cell (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 16